Heat shock protein 90 overexpression independently predicts inferior disease-free survival with differential expression of the alpha and beta isoforms in gastrointestinal stromal tumors - PubMed (original) (raw)
Heat shock protein 90 overexpression independently predicts inferior disease-free survival with differential expression of the alpha and beta isoforms in gastrointestinal stromal tumors
Chien-Feng Li et al. Clin Cancer Res. 2008.
Abstract
Purpose: Most gastrointestinal stromal tumors harbor a mutated KIT or PDGFRA receptor tyrosine kinase (RTK). Heat shock protein 90 (Hsp90) is a chaperone mediating the folding and stabilization of many oncoproteins, including KIT. An Hsp90 inhibitor, 17-AAG, can attenuate KIT activation and proliferation of gastrointestinal stromal tumor cell lines. We further evaluated Hsp90 immunoexpression and the difference between alpha and beta isoforms in gastrointestinal stromal tumor specimens.
Experimental design: Hsp90 immunostain was assessable in 306 cases on tissue microarrays of primary gastrointestinal stromal tumors and correlated with various variables and disease-free survival (DFS). RTK mutation variants, confirmed in 142 cases by sequencing with or without precedent denaturing high pressure liquid chromatography screening, were dichotomized into two prognostically different groups. Differential expression of transcript and protein isoforms was measured by real-time reverse transcription-PCR and Western blotting in 16 and 6 cases, respectively.
Results: Hsp90 overexpression (55%) significantly correlated with larger size, nongastric location, higher mitotic count and NIH risk level, Ki-67 overexpression (all P < or = 0.001), and unfavorable RTK genotypes (P = 0.020). It strongly portended inferior DFS univariately (P < 0.0001) and remained independent in multivariate analysis (P = 0.031; risk ratio, 2.44), along with high-risk category, Ki-67 overexpression, and old age. For both mRNA and protein, Hsp90beta was more abundant than Hsp90alpha, whereas the latter was significantly higher in high-risk cases.
Conclusions: Hsp90 overexpression represents a poor prognosticator that correlates with several adverse parameters, highlighting its role in disease progression and alternative therapy for high-risk, imatinib-resistant gastrointestinal stromal tumors. Hsp90alpha seems more relevant to the intrinsic aggressiveness of gastrointestinal stromal tumors, albeit less abundant than Hsp90beta.
Similar articles
- Homozygous deletion of MTAP gene as a poor prognosticator in gastrointestinal stromal tumors.
Huang HY, Li SH, Yu SC, Chou FF, Tzeng CC, Hu TH, Uen YH, Tian YF, Wang YH, Fang FM, Huang WW, Wei YC, Wu JM, Li CF. Huang HY, et al. Clin Cancer Res. 2009 Nov 15;15(22):6963-72. doi: 10.1158/1078-0432.CCR-09-1511. Epub 2009 Nov 3. Clin Cancer Res. 2009. PMID: 19887491 - The abnormalities in the p53/p21WAF1 pathway have a significant role in the pathogenesis and progression of gastrointestinal stromal tumors.
Chou YP, Lin JW, Wang CC, Chiu YC, Huang CC, Chuah SK, Tai MH, Yi LN, Lee CM, Changchien CS, Hu TH. Chou YP, et al. Oncol Rep. 2008 Jan;19(1):49-56. Oncol Rep. 2008. PMID: 18097575 - Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors.
Haller F, Gunawan B, von Heydebreck A, Schwager S, Schulten HJ, Wolf-Salgó J, Langer C, Ramadori G, Sültmann H, Füzesi L. Haller F, et al. Clin Cancer Res. 2005 Sep 15;11(18):6589-97. doi: 10.1158/1078-0432.CCR-05-0329. Clin Cancer Res. 2005. PMID: 16166437 - Gastrointestinal stromal tumors of the vermiform appendix: clinicopathologic, immunohistochemical, and molecular study of 2 cases with literature review.
Agaimy A, Pelz AF, Wieacker P, Roessner A, Wünsch PH, Schneider-Stock R. Agaimy A, et al. Hum Pathol. 2008 Aug;39(8):1252-7. doi: 10.1016/j.humpath.2007.12.016. Epub 2008 Jun 10. Hum Pathol. 2008. PMID: 18547614 Review. - Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues.
Reichardt P, Hogendoorn PC, Tamborini E, Loda M, Gronchi A, Poveda A, Schöffski P. Reichardt P, et al. Semin Oncol. 2009 Aug;36(4):290-301. doi: 10.1053/j.seminoncol.2009.06.002. Semin Oncol. 2009. PMID: 19664490 Review.
Cited by
- Maggot Extract Inhibits Cell Migration and Tumor Growth by Targeting HSP90AB1 in Ovarian Cancer.
Wang D, Wang R, Cai M, Zhang Y, Zhu Z, Weng Y, Wang L, Huang Y, Du R, Wu X, Tao G, Wang Y. Wang D, et al. J Clin Med. 2022 Oct 25;11(21):6271. doi: 10.3390/jcm11216271. J Clin Med. 2022. PMID: 36362498 Free PMC article. - Fabrication of Paclitaxel and 17AAG-loaded Poly-ε-Caprolactone Nanoparticles for Breast Cancer Treatment.
Berko YA, Funmilola AF, Akala EO. Berko YA, et al. J Pharm Drug Deliv Res. 2021 Jan;10(1):196. Epub 2021 Jan 11. J Pharm Drug Deliv Res. 2021. PMID: 33681397 Free PMC article. - Differential expression of HSP90 isoforms and their correlations with clinicopathologic factors in patients with colorectal cancer.
Kim K, Lee HW, Lee EH, Park MI, Lee JS, Kim MS, Kim K, Roh MS, Pak MG, Oh JE, Kim KM, Lee JW, Kim TG, Nam HY. Kim K, et al. Int J Clin Exp Pathol. 2019 Mar 1;12(3):978-986. eCollection 2019. Int J Clin Exp Pathol. 2019. PMID: 31933908 Free PMC article. - Hydroxysteroid 11-Beta Dehydrogenase 1 Overexpression with Copy-Number Gain and Missense Mutations in Primary Gastrointestinal Stromal Tumors.
Li CF, Liu TT, Wang JC, Yu SC, Chen YY, Fang FM, Li WS, Huang HY. Li CF, et al. J Clin Med. 2018 Nov 1;7(11):408. doi: 10.3390/jcm7110408. J Clin Med. 2018. PMID: 30388854 Free PMC article. - Hsp90ab1 stabilizes LRP5 to promote epithelial-mesenchymal transition via activating of AKT and Wnt/β-catenin signaling pathways in gastric cancer progression.
Wang H, Deng G, Ai M, Xu Z, Mou T, Yu J, Liu H, Wang S, Li G. Wang H, et al. Oncogene. 2019 Feb;38(9):1489-1507. doi: 10.1038/s41388-018-0532-5. Epub 2018 Oct 10. Oncogene. 2019. PMID: 30305727 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous